Christian Posch, Homayoun Moslehi, Luzviminda Feeney, Gary A. Green, Anoosheh Ebaee, Valentin Feichtenschlager, Kim Chong, Lily Peng, Michelle T. Dimon, Thomas ...
[18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: ...
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text ...
WAYNE, Pa., May 4, 2021 /PRNewswire/ — In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at ...
Newswise - ORLANDO, Fla. - The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented ...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced ...
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback